Last Update 16 Mar 26

EXAS: Abbott Deal Expectations And Downgrades Will Shape Event Path Forward

The analyst price target for Exact Sciences has been adjusted to reflect a revised view of slightly higher long term revenue growth and profit margins, along with a modestly higher discount rate and a lower assumed future P/E multiple, resulting in a new target of $105.81, unchanged from the prior target of $105.81.

Analyst Commentary

Recent Street research around Exact Sciences has been limited, with one identified change being a downgrade and another reference tied to a broader sector view rather than company specific fundamentals. Even with sparse details, the available commentary still offers some signals on how analysts are framing risk and potential reward for the stock.

Bullish Takeaways

Goldman Sachs includes Exact Sciences in its coverage when discussing large healthcare holdings. This can keep the stock on the radar of institutional investors focused on long term earnings power and potential integration into larger industry players.
In Goldman's view, a return to more "normalized" fundamental and valuation relationships across healthcare could help investors focus more on organic growth, execution and earnings quality at companies like Exact Sciences, rather than shorter term trading swings.
The reference to a pending acquisition of Exact Sciences in Goldman's work on Abbott signals that some investors may be evaluating the company in the context of potential corporate activity. This can influence how they think about control value and long term optionality.

Bearish Takeaways

A recent downgrade from Mizuho highlights that at least some analysts see a less favorable risk reward profile at current levels, whether due to execution, valuation, competitive pressures or a combination of these factors.
The downgrade suggests concern that current pricing may already reflect optimistic assumptions around revenue growth, margins or future P/E. This could limit upside if the company simply meets rather than beats expectations.
With one camp focusing on company specific risks and another placing Exact Sciences within broader healthcare and potential M&A themes, investors may face mixed signals that can add volatility around news flow, earnings updates or changes in sector sentiment.

What's in the News

Walgreens is working with Exact Sciences and Workflow Services to offer a streamlined path for eligible, average risk customers to request the Cologuard colorectal cancer screening test through local pharmacies. The aim is to expand access to noninvasive, at home screening that is covered by most major insurers, including Medicare and Medicaid (Client Announcements).
Workflow Services is integrating colorectal screening programs directly into Walgreens pharmacy operations, aiming to close screening gaps by making pharmacist led programs and preventative services more accessible for patients who might otherwise miss routine checks (Client Announcements).
Amalgam Rx, Privia Health and Exact Sciences are using EHR integrated workflows and proactive outreach to support colorectal cancer screening with Cologuard for eligible patients aged 45 and older. The program engaged more than 42,000 patients across two markets and processed about 23,000 screening orders within 48 hours, later scaling to reach over 100,000 patients (Product Related Announcements).
The Privia Health case study reports that this coordinated outreach reached an 84% colorectal cancer screening rate in 2024 within the program. This result is above national benchmarks and the National Colorectal Cancer Roundtable 80% goal, while also supporting value based care metrics and electronic quality reporting through better documentation in the EHR (Product Related Announcements).
Exact Sciences reports that more than 2,000,000 breast cancer patients worldwide have used its Oncotype DX Breast Recurrence Score test to help guide treatment decisions. Published models estimate average lifetime savings of about US$10,000 per patient in the US healthcare system, and the test is in widespread use across more than 100 countries (Product Related Announcements).

Valuation Changes

Fair Value: $105.81 remains unchanged, with the updated model producing the same output as the prior estimate.
Discount Rate: 7.24% to 7.26%, risen slightly, which generally makes future cash flows worth a bit less in today's terms.
Revenue Growth: 11.03% to 11.79%, risen slightly, implying a modestly higher long term growth assumption for dollar revenue.
Net Profit Margin: 7.44% to 7.51%, risen slightly, reflecting a small improvement in expected long run profitability.
Future P/E: 77.79x to 75.50x, fallen slightly, pointing to a modestly lower valuation multiple assumption on future earnings.

29 views

Key Takeaways

Broadening payer coverage and demographic trends toward an older population are positioning Exact Sciences for sustained and expanding revenue opportunities from core and new product offerings.
Cost optimization initiatives, operational scale, and tech-driven efficiency improvements are enhancing profitability while product portfolio diversification increases market competitiveness and revenue streams.
Heavy reliance on Cologuard, uncertain returns from costly innovation, and rising competition in cancer screening threaten sustained growth, margins, and strategic positioning.

Catalysts

About Exact Sciences

Provides cancer screening and diagnostic test products in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Expanding payer coverage (notably new contracts with top insurers like Humana and Centene and Medicare reimbursement for new products) and increasing government screening mandates are expected to substantially boost accessibility and recurring revenue for core products such as Cologuard and Oncodetect, supporting sustained top-line growth.
The ongoing demographic shift toward an aging population-coupled with Exact Sciences' broader early detection portfolio (Cologuard Plus, blood-based screening via Freenome, and the upcoming MCED test CancerGuard)-is set to expand the addressable market significantly and position the company to capture future volume-driven revenue growth as cancer incidence increases.
Accelerated adoption of preventative diagnostics and personalized medicine by providers and patients is fueling higher screening rates, as evidenced by record physician engagement, robust rescreen rates, and digital ordering growth, which should further drive revenue and margin expansion as Exact's test suite gains share.
Multi-year operational cost optimization initiatives (targeting $150M in annual savings by 2026 via automation, AI-driven lab/process efficiencies, and reduced G&A spend) are establishing a foundation for expanding EBITDA and net margins over time, especially as scale effects take hold.
Strategic licensing of Freenome's blood-based colorectal cancer screening technology provides optionality to rapidly address a key market niche (screening-resistant patients) and accelerate time-to-market, making the portfolio more competitive and diversified while driving incremental revenue and leveraging existing sales infrastructure.

Exact Sciences Earnings and Revenue Growth

Exact Sciences Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Exact Sciences's revenue will grow by 11.6% annually over the next 3 years.
Analysts assume that profit margins will increase from -34.2% today to 6.8% in 3 years time.
Analysts expect earnings to reach $277.2 million (and earnings per share of $1.53) by about September 2028, up from $-1.0 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $450 million in earnings, and the most bearish expecting $118 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 56.5x on those 2028 earnings, up from -9.3x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
Analysts expect the number of shares outstanding to grow by 2.29% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.08%, as per the Simply Wall St company report.

Exact Sciences Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Ongoing high R&D and M&A expenditures, mixed with past underperformance from acquired or internally-developed assets (such as blood-based CRC screening and the Thrive acquisition), raises doubts that these investments will deliver reliable future returns, increasing the risk of continued negative net margins or weak earnings improvement.
Exposure to increasing competition in both stool
and blood-based colorectal cancer screening (e.g., Guardant, future Freenome progress, traditional colonoscopy preference), and potential commoditization of molecular diagnostics, may create margin pressure and limit Exact Sciences' revenue growth and pricing power over the long term.
Exact's core revenue is still heavily concentrated in Cologuard, making it vulnerable to shifts in screening guidelines, payer policy, or disruptive new technologies-if blood-based tests gain broader guideline support or if reimbursement for stool tests weakens, revenue and earnings could decline.
The future market for blood-based CRC screening and MCED testing remains uncertain, as current guideline bodies are not yet fully supportive, real-world clinical utility is questioned (especially in pre-cancer detection), and payers may delay or deny reimbursement, potentially stalling adoption and pipeline monetization.
The company's move to license rather than own key next-generation blood-based technology (Freenome), and granting data access to a potential competitor, could weaken its competitive moat in multi-cancer early detection, creating new strategic risks and heightening future threats to long-term revenue growth and market share.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $63.143 for Exact Sciences based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $80.0, and the most bearish reporting a price target of just $50.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $4.1 billion, earnings will come to $277.2 million, and it would be trading on a PE ratio of 56.5x, assuming you use a discount rate of 7.1%.
Given the current share price of $49.27, the analyst price target of $63.14 is 22.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Exact Sciences?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

EXAS: Cancer Screening Expansion Will Balance Challenges From Blood Test Data